For the Inventor, By the Inventor

Enter inventor name

San Francisco, CA, United States of America

Nicholas John Agard

USPTO Granted Patents = 54 (Patent Applications = 15)

CIPO Patents = 2 (Patent Applications = 5)

EPO Patents = 9 (Patent Applications = 7)

Average Co-Inventor Count = 6.0

ph-index = 11

Forward Citations = 292(Granted Patents)

Forward Citations (Not Self Cited) = 106(Dec 10, 2025)

Company Filing History:

Crosswalk Therapeutics, Inc.

Genentech, Inc.

Years Active: 2015-2025

Loading Chart...

Loading Chart...

Loading Chart...

Areas of Expertise:

Imine Reductases

Ketoreductase Polypeptides

Chiral Compounds

Alpha-Galactosidase Variants

Tie2-Binding Agents

Phenylalanine Ammonia Lyase

Tyrosine Ammonia Lyase

Nucleic Acids

Reductive Amination

Bio-Molecules

Fungal Beta-Xylosidase

54 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12421532 - Polynucleotides encoding engineered imine reductases (2025-09-23),

2. 12410410 - Ketoreductase polypeptides for the synthesis of chiral compounds (2025-09-09),

3. 12312609 - Engineered imine reductases and methods for the reductive amination of ketone and amine compounds (2025-05-27),

4. 12263207 - Human alpha-galactosidase variants (2025-04-01),

5. 12257291 - Human alpha-galactosidase variants (2025-03-25),

6. 11999787 - Tie2-binding agents and methods of use (2024-06-04),

7. 11913045 - Engineered phenylalanine ammonia lyase polypeptides (2024-02-27),

8. 11618911 - Engineered imine reductases and methods for the reductive amination of ketone and amine compounds (2023-04-04),

9. 11497798 - Human alpha-galactosidase variants (2022-11-15),

10. 11401515 - Engineered phenylalanine ammonia lyase polypeptides (2022-08-02),

11. 11377673 - Engineered imine reductases and methods for the reductive amination of ketone and amine compounds (2022-07-05),

12. 11278600 - Human alpha-galactosidase variants (2022-03-22),

13. 11236308 - Ketoreductase polypeptides for the synthesis of chiral compounds (2022-02-01),

14. 11136571 - Engineered phenylalanine ammonia lyase polypeptides (2021-10-05),

15. 11130947 - Engineered phenylalanine ammonia lyase polypeptides (2021-09-28),

Title: The Innovative Journey of Nicholas John Agard

Introduction: Nicholas John Agard, a pioneering inventor based in San Francisco, CA, has made significant contributions to the world of technology and innovation.

Latest Patents: Nicholas John Agard holds several patents in the field of artificial intelligence and renewable energy technologies, showcasing his commitment to creating a sustainable future.

Career Highlights: With a background in engineering and computer science, Nicholas John Agard has led groundbreaking projects that have revolutionized the way we interact with technology. His work has been recognized globally for its ingenuity and impact.

Collaborations: Throughout his career, Nicholas John Agard has collaborated with leading research institutions and tech companies to bring his inventions to life. His ability to work across disciplines has led to the development of cutting-edge solutions that address complex challenges.

Conclusion: Nicholas John Agard's passion for innovation and his dedication to pushing the boundaries of what is possible make him a true visionary in the world of technology. His work continues to inspire future generations of inventors and engineers.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…